

**In the Claims:**

1 . (Currently Amended) An isolated RELP protein human Ig derived protein [or specified portion or variant], comprising at least one human variable [and human constant] region, wherein said human Ig derived protein or specified portion or variant specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence, selected from the group consisting of SEQ ID NO[S]: 2[, 4, 5, 6, 7, 8, 9, 10, and/or 11].

2 . (Currently Amended) An RELP protein human Ig derived protein or specified portion or variant according to claim 1[65], wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least  $10^{-9}$  M.

3 . (Currently Amended) An RELP protein human Ig derived protein or specified portion or variant according to claim 1[65], wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least  $10^{-11}$  M.

4 . (Currently Amended) An RELP protein human Ig derived protein or specified portion or variant, according to claim 1 [65], wherein said human Ig derived protein or specified portion or variant binds with an affinity of at least  $10^{-12}$  M.

5 . (Currently Amended) An RELP protein human Ig derived protein or specified portion or variant according to claim 1 [65], wherein said human Ig derived protein or specified portion or variant substantially neutralizes at least one activity of at least one RELP protein.

6 . (Now Canceled)

7 . (Currently Amended) An isolated RELP protein human Ig derived protein or specified portion or variant, comprising an isolated human Ig derived protein or specified portion or variant encoded by a nucleic acid [according to claim 6] comprising a nucleic acid that encodes a RELP Ig derived protein according to claim 1.

8 . (Now Canceled)

9 . (Now Canceled)

10 . (Now Canceled)

11 . (Now Canceled)

12 . (Now Canceled)

13 . (Now Canceled)

14 . (Now Canceled)

Appl No. 10/099,791

Amdt. Dated January 20, 2005

Reply to Office Communication of October 20, 2004

15 . (Original) An RELP protein human Ig derived protein or specified portion or variant composition, comprising at least one isolated RELP protein human Ig derived protein or specified portion or variant according to claim 1, and a carrier or diluent.

16 . (Original) A composition according to claim 15, wherein said carrier or diluent is pharmaceutically acceptable.

17 . (Original) A composition according to claim 15, further comprising at least one compound or protein selected from at least one of a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropoietin, a filgrastim, a sargramostim, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha, a cytokine, a cytokine antagonist.

18 . (Now Canceled)

19 . (Now Canceled)

20 . (Now Canceled)

21 . (Now Canceled)

22 . (Now Canceled)

23 . (Now Canceled)

24 . (Now Canceled)

25 . (Original) A medical device, comprising at least one RELP protein human Ig derived protein or specified portion or variant according to claim 1, wherein said device is suitable to contacting or administering said at least one RELP protein human Ig derived protein or specified portion or variant by at least one mode selected from intravenous, intramuscular, bolus, intraperitoneal, subcutaneous, respiratory, inhalation, nasal, vaginal, rectal, buccal, sublingual, intranasal, subdermal, or transdermal.

26 . (Original) A human immunoglobulin light chain RELP protein or portion thereof, comprising at least one portion of a variable region comprising at least one human Ig derived protein fragment according to claim 1.

Appl No. 10/099,791

Amdt. Dated January 20, 2005

Reply to Office Communication of October 20, 2004

27 . (Original) A human immunoglobulin heavy chain or portion thereof, comprising at least one portion of a variable region comprising at least one RELP protein human Ig derived protein fragment according to claim 1.

28 . (Original) A human Ig derived protein or specified portion or variant thereof, wherein said human Ig derived protein or specified portion or variant binds the same epitope or antigenic region as a RELP protein human Ig derived protein or specified portion or variant according to claim 1.

29 . (Original) A formulation comprising at least one RELP protein human Ig derived protein or specified portion or variant according to claim 1, and at least one selected from sterile water, sterile buffered water, or at least one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an aqueous diluent.

30 . (Original) A formulation of Claim 29, wherein the concentration of RELP protein human Ig derived protein or specified portion or variant is about 0.1 mg/ml to about 100 mg/ml.

31 . (Original) A formulation of Claim 29, further comprising an isotonicity agent.

32 . (Original) A formulation of Claim 29, further comprising a physiologically acceptable buffer.

33 . (Original) A formulation comprising at least one RELP protein human Ig derived protein or specified portion or variant according to Claim 1 in lyophilized form in a first container, and an optional second container comprising at least one of sterile water, sterile buffered water, or at least one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an aqueous diluent.

34 . (Original) A formulation of Claim 33, wherein the concentration of RELP protein human Ig derived protein or specified portion or variant is reconstituted to a concentration of about 0.1 mg/ml to about 500 mg/ml.

35 . (Original) A formulation of Claim 33, further comprising an isotonicity agent.

36 . (Original) A formulation of Claim 33, further comprising a physiologically acceptable buffer.

37 . (Now Canceled)

Appl No. 10/099,791

Amdt. Dated January 20, 2005

Reply to Office Communication of October 20, 2004

38 . (Now Canceled)

39 . (Original) An article of manufacture for human pharmaceutical use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one RELP protein human Ig derived protein or specified portion or variant according to claim 1.

40 . (Original) The article of manufacture of Claim 39, wherein said container is a glass or plastic container having a stopper for multi-use administration.

41 . (Original) The article of manufacture of Claim 39, wherein said container is a blister pack, capable of being punctured and used in intravenous, intramuscular, bolus, intraperitoneal, subcutaneous, respiratory, inhalation, nasal, vaginal, rectal, buccal, sublingual, intranasal, subdermal, or transdermal administration.

42 . (Original) The article of manufacture of claim 39, wherein said container is a component of a intravenous, intramuscular, bolus, intraperitoneal, subcutaneous, respiratory, inhalation, nasal, vaginal, rectal, buccal, sublingual, intranasal, subdermal, or transdermal delivery device or system.

43 . (Original) The article of manufacture of Claim 39, wherein said container is a component of an injector or pen-injector device or system for intravenous, intramuscular, bolus, intraperitoneal, subcutaneous, respiratory, inhalation, nasal, vaginal, rectal, buccal, sublingual, intranasal, subdermal, or transdermal.

44 . (Original) A method for preparing a formulation of at least one RELP protein human Ig derived protein or specified portion or variant, comprising admixing at least one RELP protein human Ig derived protein or specified portion or variant according to claim 1 in at least one buffer containing saline or a salt.

45 . (Now Canceled)

46 . (Now Canceled)

47 . (Now Canceled)

48 . (Now Canceled)

49 . (Now Canceled)

50 . (Once Amended) At least one RELP protein human Ig derived protein or specified portion or variant according to Claim 1, produced by a method [according to claim 45] comprising providing a host cell, transgenic animal, transgenic plant or plant cell capable of expressing in recoverable amounts said human Ig derived protein or specified portion or variant.

51 . (Now Canceled)

Appl No. 10/099,791

Amdt. Dated January 20, 2005

Reply to Office Communication of October 20, 2004

52 . (Original) An RELP protein human Ig derived protein or specified portion or variant, wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least  $10^{-9}$  M.

53 . (Original) An RELP protein human Ig derived protein or specified portion or variant according to claim 52, wherein said human Ig derived protein or specified portion or variant binds RELP protein with an affinity of at least  $10^{-11}$  M.

54 . (Original) An RELP protein human Ig derived protein or specified portion or variant, according to claim 53, wherein said human Ig derived protein or specified portion or variant binds with an affinity of at least  $10^{-12}$  M.

55 . (Now Canceled)